Finance / IDEV (Indevus Pharmaceuticals Inc.) Sell

Ranking Healthcare Stocks YTD Performance Ranking | Company (Ticker) | Year-to-Date Performance 1 HeartWare International, Inc. (NASDAQ:HTWR) 8721.6% 2 Vasogen Inc. (USA) (NASDAQ:IPCI) 2344.3% 3 Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) 1956.0% 4 Human Genome Sciences (NASDAQ:HGSI) 1191.5% 5 Opexa Therapeutics Inc. (NASDAQ:OPXA) 979.0% 6 OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI) 977.3% 7 Speedus...

[b]Ranking Healthcare Stocks YTD Performance[/b] Ranking | Company (Ticker) | Year-to-Date Performance 1 HeartWare International, Inc. (NASDAQ:HTWR) 8721.6% 2 Vasogen Inc. (USA) (NASDAQ:IPCI) 2344.3% 3 Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) 1956.0% 4 Human Genome Sciences (NASDAQ:HGSI) 1191.5% 5 Opexa Therapeutics Inc. (NASDAQ:OPXA) 979.0% 6 OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI) 977.3% 7 ...

Endo 3Q profit falls on Indevus buyout costs Endo Pharmaceuticals' 3rd-quarter profit dips on buyout costs; pain drugs drive revenue On 8:07 am EDT, Thursday October 29, 2009 Buzz up! 0 Print.Companies:Endo Pharmaceuticals Holdings Inc. CHADDS FORD, Pa. (AP) -- Drug developer Endo Pharmaceuticals Holdings Inc. said Thursday its third-quarter profit plunged on charges mainly related to the buyout ...

Quote: Originally Posted by marcus300 I know the release date is soon or from what ive read, but I didnt see anything about a smaller dose, there have been studies going on for 8 and 9yrs with 1000mgs and ive not seen anything regarding a smaller dose. I think if people are really happy with their HRT therapy treatment they should...

Endo Pharmaceuticals Announces Expiration of Cash Tender Offer for Ledgemont PhaRMA(SM) Secured 16% Notes Press Release Source: Endo Pharmaceuticals On Friday September 25, 2009, 9:02 am EDT Buzz up! 0 Print.Companies:Endo Pharmaceuticals Holdings Inc. CHADDS FORD, Pa., Sept. 25 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP - News) announced today the expiration and final results ...

DOW JONES NEWSWIRES Endo Pharmaceuticals Holdings Inc. (ENDP) signed an agreement with ProStrakan Group PLC (PSK.LN) for the exclusive right to sell the U.K. drug company's Fortesta testosterone-replacement therapy gel in the U.S. The deal is the latest move by the U.S. specialty drug company to expand into new markets. Endo has been expanding beyond pain management into urology, ...